Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients

Abstract

Purpose:

Blockade of the angiotensin-renin system, with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), has been shown to improve cardiac outcomes following myocardial infarction and delay progression of heart failure. Acromegaly is associated with a disease-specific cardiomyopathy, the pathogenesis of which is poorly understood.

Methods:

The cardiac indices of patients with active acromegaly with no hypertension (Group A, n=4), established hypertension not taking ACEi/ARBs (Group B, n=4) and established hypertension taking ACEi/ARBs (Group C, n=4) were compared using cardiac magnetic imaging.

Results:

Patients taking ACEi/ARBs had lower end diastolic volume index (EDVi) and end systolic volume index (ESVi) than the other 2 groups ([C] 73.24 vs. [A] 97.92 vs. [B] 101.03 ml/m², ANOVA p=0.034, B vs. C p<0.01). Groups A and B had EDVi and ESVi values at the top of published reference range values; Group C had values in the middle of the range.

Conclusion:

Acromegaly patients on ACEi/ARBs for hypertension demonstrate improved cardiac indices compared to acromegaly patients with hypertension not taking these medications. Further studies are needed to determine if these drugs have a beneficial cardiac effect in acromegaly in the absence of demonstrable hypertension.

Key words

pituitary - acromegaly - cardiac magnetic resonance - renin-angiotensin

• References

• 1 Suzuki H, Kusuyama T, Omori Y. et al. Inhibitory effect of candesartan cilexetil on left ventricular remodeling after myocardial infarction. Int Heart J 2006; 47: 715-725
• 2 Bazzino O, Navarro Estrada JL, Sosa Liprandi A. et al. Early treatment with low-dose enalapril after acute myocardial infarction: an equilibrium radionuclide angiographic study. Enalapril despues del Infarto (EDI) Trial Investigators. J Nucl Cardiol 1997; 4: 133-139
• 3 Greenberg B, Quinones MA, Koilpillai C. et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995; 91: 2573-2581
• 4 Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994; 15: 555-573
• 5 Colao A, Marzullo P, Di Somma C. et al. Growth hormone and the heart. Clin Endocrinol 2001; 54: 137-154
• 6 Clayton RN. Cardiovascular function in acromegaly. Endocr Rev 2003; 24: 272-277
• 7 Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER. et al. Normal values for cardiovascular magnetic resonance in adults and children. J Cardiovasc Magn Reson 2015; 17: 29
• 8 Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: A consensus paper from an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35: 569-582
• 9 Konstam MA, Rousseau MF, Kronenberg MW. et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992; 86: 431-438
• 10 Konstam MA, Kronenberg MW, Rousseau MF. et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 1993; 88: 2277-2283
• 11 Fazio S, Cittadini A, Sabatini D. et al. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study. Eur Hear J 1993; 14: 26-33
• 12 Marks P, Vincent R, Wilson B. et al. Aldosterone in acromegaly. Am J Med Sci 1984; 287: 16-19
• 13 van Eickels M, Vetter H, Grohé C. Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation. Br J Pharmacol 2000; 131: 1592-1596
• 14 Hansson L, Lindholm LH, Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616